Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

St. Jude's Newly Approved Axium Stimulator Could Be Market Game-Changer

This article was originally published in The Gray Sheet

Executive Summary

St. Jude followed through on its 2015 acquisition of start-up Spinal Modulation with an FDA approval of the Axium neurostimulator for chronic intractable pain. It's the first such device to target the dorsal root ganglion and could expand the overall size of the spinal cord stimulation market.

Advertisement

Related Content

St. Jude: Neuromodulators Could Be Key To Fighting Opioid Epidemic
Neuromodulation 2016: Competition Heats Up In Spinal Cord Stim Market
Neuromodulation 2015: Innovation Expands Opportunities In Chronic Pain

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register